Principal component analysis of brain metabolism in symptomatic Alzheimer's disease patients: A positron emission tomography with 18F‐fluorodeoxyglucose (PET‐FDG) study

Background Patients with symptomatic Alzheimer's Disease (AD) usually present alterations in their cerebral metabolism measured by Positron Emission Tomography with 18F‐fluorodeoxyglucose (PET‐FDG). In the amnestic AD phenotype, the regional differences reported between patients with Mild Cognitive Impairment due to Alzheimer's Disease (MCI‐AD) and AD Dementia (ADD) have not been consistent. Within the ATN scheme, this study detects Neurodegeneration (N). There are no published studies that correlated the metabolic value of each cortical region and the quantification of cognitive performance. Objective: To analyze brain metabolism by regions measured by Positron Emission Tomography with PET‐FDG in patients with MCI‐AD and ADD, and correlate the regional metabolic values with the severity of neuropsychological clinical variables. Method In this cross‐sectional study, 24 patients with MCI‐AD and 22 with ADD were included , all right‐handed and PET–PIB positive, matched by sex, age, and education, with differences in different cognitive variables (p